Cargando…

Accurate digital quantification of tau pathology in progressive supranuclear palsy

The development of novel treatments for Progressive Supranuclear Palsy (PSP) is hindered by a knowledge gap of the impact of neurodegenerative neuropathology on brain structure and function. The current standard practice for measuring postmortem tau histology is semi-quantitative assessment, which i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pansuwan, Tanrada, Quaegebeur, Annelies, Kaalund, Sanne S., Hidari, Eric, Briggs, Mayen, Rowe, James B., Rittman, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634011/ https://www.ncbi.nlm.nih.gov/pubmed/37946288 http://dx.doi.org/10.1186/s40478-023-01674-y

Ejemplares similares

Validation of the new pathology staging system for progressive supranuclear palsy
por: Briggs, Mayen, et al.
Publicado: (2021)

In Vivo (18)F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
por: Malpetti, Maura, et al.
Publicado: (2022)

Falls in Progressive Supranuclear Palsy
por: Brown, Fraser S., et al.
Publicado: (2019)

Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity
por: Kaalund, Sanne Simone, et al.
Publicado: (2020)

Progressive supranuclear palsy: diagnosis and management
por: Rowe, James B, et al.
Publicado: (2021)

Managing cognition in progressive supranuclear palsy
por: Rittman, Timothy, et al.
Publicado: (2016)

Tau burden and the functional connectome in Alzheimer’s disease and progressive supranuclear palsy
por: Cope, Thomas E, et al.
Publicado: (2018)

Distribution patterns of tau pathology in progressive supranuclear palsy
por: Kovacs, Gabor G., et al.
Publicado: (2020)

Co‐Occurrence of Apathy and Impulsivity in Progressive Supranuclear Palsy
por: Kok, Zi Q., et al.
Publicado: (2021)

Structural and Functional Thalamic Changes in Progressive Supranuclear Palsy
por: Tan, Sean YW, et al.
Publicado: (2022)

Towards accurate and unbiased imaging-based differentiation of Parkinson’s disease, progressive supranuclear palsy and corticobasal syndrome
por: Correia, Marta M, et al.
Publicado: (2020)

Structural correlates of survival in Progressive Supranuclear Palsy
por: Street, Duncan, et al.
Publicado: (2023)

Altered network stability in progressive supranuclear palsy
por: Whiteside, David J, et al.
Publicado: (2021)

Neuroinflammation predicts disease progression in progressive supranuclear palsy
por: Malpetti, Maura, et al.
Publicado: (2021)

Characterization of tau oligomeric seeds in progressive supranuclear palsy
por: Gerson, Julia E, et al.
Publicado: (2014)

SUMO1 Modification of Tau in Progressive Supranuclear Palsy
por: Takamura, Hironori, et al.
Publicado: (2022)

Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration
por: Briel, Nils, et al.
Publicado: (2020)

Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants
por: Street, Duncan, et al.
Publicado: (2021)

Different decision deficits impair response inhibition in progressive supranuclear palsy and Parkinson’s disease
por: Zhang, Jiaxiang, et al.
Publicado: (2016)

Latent trait modeling of tau neuropathology in progressive supranuclear palsy
por: Kouri, Naomi, et al.
Publicado: (2021)

Actin-binding protein filamin-A drives tau aggregation and contributes to progressive supranuclear palsy pathology
por: Tsujikawa, Koyo, et al.
Publicado: (2022)

Does the Anti‐Tau Strategy in Progressive Supranuclear Palsy Need to Be Reconsidered? No
por: Höglinger, Günter U.
Publicado: (2021)

Tau pathology in aged cynomolgus monkeys is progressive supranuclear palsy/corticobasal degeneration- but not Alzheimer disease-like -Ultrastructural mapping of tau by EDX-
por: Uchihara, Toshiki, et al.
Publicado: (2016)

Language impairment in progressive supranuclear palsy and corticobasal syndrome
por: Peterson, Katie A., et al.
Publicado: (2019)

Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration
por: Martínez-Maldonado, Alejandra, et al.
Publicado: (2021)

Network connectivity and structural correlates of survival in progressive supranuclear palsy and corticobasal syndrome
por: Whiteside, David J., et al.
Publicado: (2023)

(18)F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy
por: Liu, Feng-Tao, et al.
Publicado: (2023)

Zolpidem in Progressive Supranuclear Palsy
por: Dash, Sandip K.
Publicado: (2013)

Genetics of Progressive Supranuclear Palsy
por: Im, Sun Young, et al.
Publicado: (2015)

Midbrain catecholaminergic neurons co-express α-synuclein and tau in progressive supranuclear palsy
por: Erro Aguirre, María Elena, et al.
Publicado: (2015)

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy
por: Smith, Ruben, et al.
Publicado: (2016)

Reorganisation of brain networks in frontotemporal dementia and progressive supranuclear palsy()
por: Hughes, Laura E., et al.
Publicado: (2013)

Distinct subcortical tau burden: The tau pallido‐claustral ratio separates progressive supranuclear palsy and corticobasal degeneration
por: Zhao, Chelsey ShengQi, et al.
Publicado: (2021)

Florid Nonmotor Manifestations of a Pathologically proven Progressive Supranuclear Palsy
por: Shin, Chaewon, et al.
Publicado: (2018)

The genetic and clinico‐pathological profile of early‐onset progressive supranuclear palsy
por: Jabbari, Edwin, et al.
Publicado: (2019)

Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies
por: Montalbano, Mauro, et al.
Publicado: (2022)

Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures
por: Valentino, Rebecca R., et al.
Publicado: (2020)

Neurophysiological consequences of synapse loss in progressive supranuclear palsy
por: Adams, Natalie E, et al.
Publicado: (2022)

Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer’s disease
por: Coughlin, David G., et al.
Publicado: (2022)

‘Hummingbird’ sign in progressive supranuclear palsy
por: Shukla, Rakesh, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_62irvo0ij3ivau42jvg87srrsm